# Brian I. Rini

Source: https://onco.cc/people/brian-rini/  
OnCo record `brian-rini` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer.

## Summary

Brian Rini was principal investigator of KEYNOTE-426, the trial showing pembrolizumab plus axitinib improves survival over sunitinib in first-line advanced renal cell carcinoma, and of IMmotion151 (atezolizumab plus bevacizumab). He has led studies of active surveillance in metastatic RCC and of biomarkers of immunotherapy response. He directs clinical trials at Vanderbilt-Ingram.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: rcc; immunotherapy; trialist
- Role: Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research
- Specialisms: Renal cell carcinoma; Immunotherapy combinations; Antiangiogenic therapy; Trial design

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Vanderbilt-Ingram Cancer Center](https://onco.cc/institutions/vanderbilt-ingram/)
- trials: [KEYNOTE-426](https://onco.cc/trials/keynote-426/)

---
JSON: https://onco.cc/api/v1/entities/brian-rini.json